TPD Disease Landscape Webinar
Targeted Protein Degradation continues to progress as a therapeutic area with huge potential, and 2023 is shaping up to be a landmark year for the degradation community. As we advance highly valuable degrader compounds closer to the clinic, we were thrilled to present to the community at the recent 3rd Targeted Protein Degradation Summit.
Offering the opportunity to explore the data delivered, this session provided a deep dive into the pipeline, including:
An overview of the current TPD landscape
A deep-dive into the oncology scope exploring preclinical and clinical indications
Insights into the emerging non-oncology indications for novel degrader and stabilizer technologies
The immune tolerance landscape is nothing but dynamic; in our recent webinar, our expert panel discussed the obstacles in treating autoimmune diseases with T Cell therapy approaches and the strategies the developers are utilizing to overcome these obstacles. Key aspects explored included:
- A comprehensive overview of the competitive T Cell therapy within the immune-mediated disease space
- Insights into the emerging trends of Treg therapies
- A picture of what we can likely expect ahead based on recent approvals and late-stage activity
Our Experts
Rachel East
House Speaker
Lead Research Analyst
Beacon
Frank Plowden
Moderator
Account Manager
Beacon
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
